Personalised Cancer Medicine Flashcards 2025
Indications determined by the organ of origin
Lung Cancer
Standard
Recommended
Currently not recommended
- EGFR
- ALK
- ROS1
- PDL-1
- RET*
- NTRK*
- KRAS y MET*
- BRAF V600
- NGS**
- HER2
- NRG1
* in tumors lacking driver mutations
** in biopsies with little sample; Approved in the USA as accompanying diagnosis of EGFR and ALK inhibitors
** in biopsies with little sample; Approved in the USA as accompanying diagnosis of EGFR and ALK inhibitors
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. Isla D, Lozano MD, Paz-Ares L, et al. Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad
Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish
Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol. 2023 Apr-Jun;56(2):97-112. Spanish. doi: 10.1016/j.patol.2023.02.002.
2. Colomer R, Mondejar R, Romero-Laorden N et al,. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.
3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491- 1505. doi: 10.1016/j.annonc.2020.07.014.
4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S
2. Colomer R, Mondejar R, Romero-Laorden N et al,. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.
3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491- 1505. doi: 10.1016/j.annonc.2020.07.014.
4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S
